Phaseline

Targets › CA1

CA1 (Carbonic anhydrase 1): drug programs, companies and trials

3 programs from 3 companies in 22 trials: 8 Phase 1, 7 Phase 4, 6 Phase 2, 1 Phase 3; Ophthalmology, Neurology, Cardiovascular; next expected readout Dec 2026.

Catalyzes the reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. (UniProt, P00915)

Open in Phaseline: the race on CA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Prisma Health-UpstateMethocarbamol
Carbonic anhydrase I inhibitor
CA1Phase 4Ventral HerniaJun 2027
University of Colorado, DenverMethazolamide
Carbonic anhydrase VII inhibitor; Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor
CA7, CA1, CA2, CA4Phase 4Glaucoma, Open-Angle–
ShionogiAcetazolamide
Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor; Carbonic anhydrase XII inhibitor
CA1, CA2, CA12, CA4Phase 2Sleep Apnea; Hypobaric Hypoxia; High Altitude Effects; Post Operative Pain …Dec 2026

Conditions

Sleep Apnea (3) Obstructive Sleep Apnea (3) Glaucoma, Open-Angle (1) Hypobaric Hypoxia (1) High Altitude Effects (1) Post Operative Pain (1) Sleep Disordered Breathing (1) Acute Heart Failure (1) Type 1 Diabetes (1) Acute Decompensated Heart Failure (1) Central Sleep Apnea Comorbid With Opioid Use (1) Malignant Glioma of Brain (1)

Modalities

small molecule (3)

Companies

University of Colorado, Denver (1) Shionogi (1) Prisma Health-Upstate (1)

Related targets

CA2 (2) CA4 (2) CA7 (1) CA12 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.